Not sure about the treatment regimens. Can't see 177Lu-J591 (rosapatamab) being administered closer together - circulating radionuclide damages blood cells and also marrow (marrow toxicity is the major disadvantage for J591), so you need to leave enough time (weeks) for the body to replenish blood cells before re-treating. This already occurs with 177Lu-PSMA-617 (and other radionuclide therapies) spaced at 8 weeks.
617 has been studied much more widely than J591 - novartis did a good job getting the product out there and used in multicentre trials.
FYI there has been some interest in combining 617 and J591 therapies - even a phase I trial based in Weill Cornell (177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC - Full Text View - ClinicalTrials.gov)
Not sure about the treatment regimens. Can't see 177Lu-J591...
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.19 |
Change
0.780(4.24%) |
Mkt cap ! $6.421B | |||
| Open | High | Low | Value | Volume |
| $18.85 | $19.19 | $18.78 | $22.02M | 1.155M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2216 | $19.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.20 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |